Intellia Therapeutics, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15.0M | 23.0M | 13.8M | 14.2M | 16.6M | 12.9M | 9.1M | 7.0M |
| Cost of Goods Sold | 2.2M | 6.0M | 78.9M | 80.5M | 0 | 116.9M | 109.2M | 2.6M |
| Gross Profit | 12.8M | 17.0M | -65.2M | -66.3M | 16.6M | -104.0M | -100.1M | 4.4M |
| R&D Expenses | 80.7M | 88.7M | 94.7M | 97.0M | 108.4M | 116.9M | 123.4M | 111.6M |
| Operating Expenses | 113.4M | 115.7M | 46.3M | 43.7M | 137.4M | 32.4M | 44.7M | 143.4M |
| Operating Income | -100.5M | -98.7M | -111.5M | -110.0M | -120.8M | -136.4M | -144.8M | -139.0M |
| Other Income / Gains | 4.3M | 2.9M | 10.2M | 8.7M | 6.5M | 7.5M | 9.1M | -7.9M |
| Net Income | -96.2M | -95.8M | -101.3M | -101.3M | -114.3M | -128.9M | -135.7M | -147.0M |
| EPS (Diluted) | -0.81 | -0.83 | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 | -1.52 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.854 | 0.739 | -4.728 | -4.653 | 1.00 | -8.079 | -10.983 | 0.626 |
| General And Administrative Expenses | 34.8M | 33.1M | 30.5M | 27.2M | 29.0M | 32.4M | 30.5M | 31.8M |
| Selling And Marketing Expenses | 0 | 0 | 15.8M | 16.5M | 0 | 0 | 14.2M | 0 |
| Selling General And Administrative Expenses | 34.8M | 33.1M | 46.3M | 43.7M | 29.0M | 32.4M | 44.7M | 31.8M |
| Other Expenses | -2.2M | -6.0M | -94.7M | -97.0M | 0 | -116.9M | -123.4M | 0 |
| Cost And Expenses | 115.6M | 121.7M | 125.3M | 124.2M | 137.4M | 149.3M | 153.9M | 146.0M |
| Interest Income | 5.2M | 6.5M | 6.7M | 7.4M | 8.6M | 10.6M | 12.1M | 12.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation And Amortization | 2.2M | 377K | 4.9M | 2.5M | 2.5M | 2.6M | 2.6M | 2.6M |
| Ebitda | -94.0M | -95.4M | -96.4M | -98.8M | -111.8M | -126.3M | -133.1M | -144.4M |
| Ebitdaratio | -6.249 | -4.145 | -6.994 | -6.934 | -6.726 | -9.813 | -14.609 | -20.753 |
| Operating Income Ratio | -6.681 | -4.289 | -8.089 | -7.722 | -7.266 | -10.599 | -15.89 | -19.986 |
| Income Before Tax | -96.2M | -95.8M | -101.3M | -101.3M | -114.3M | -128.9M | -135.7M | -147.0M |
| Income Before Tax Ratio | -6.395 | -4.162 | -7.352 | -7.108 | -6.876 | -10.012 | -14.895 | -21.126 |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income Ratio | -6.395 | -4.162 | -7.352 | -7.108 | -6.876 | -10.012 | -14.895 | -21.126 |
| Epsdiluted | -0.81 | -0.83 | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 | -1.52 |
| Weighted Average Shs Out | 118.5M | 108.4M | 110.2M | 103.7M | 103.5M | 101.9M | 101.0M | 97.0M |
| Weighted Average Shs Out Dil | 118.5M | 108.4M | 110.2M | 103.7M | 103.5M | 101.9M | 101.0M | 97.0M |